Organon & Co. (OGN) key performance indicators and operating metrics (16 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Established Brands Revenue | 880M | FY2026-Q1 |
| Women’s Health Revenue | 389M | FY2026-Q1 |
| Biosimilars Revenue | 173M | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization Margin (Non-GAAP) | 28.40 percent | FY2026-Q1 |
| Adjusted Diluted Earnings Per Share (Non-GAAP) | 0.71 USD_per_share | FY2026-Q1 |
| Adjusted EBITDA (Non-GAAP) | 415M | FY2026-Q1 |
| Other Revenue | 18M | FY2026-Q1 |
| Non-GAAP Adjusted Net Income | 165M | FY2025-Q4 |
| General Medicines: Established Brands revenue | 913M | FY2025-Q4 |
| Adjusted Gross Margin (Non-GAAP) | 56.70 percent | FY2025-Q4 |
| Net leverage ratio | 4.30 ratio | FY2025-Q4 |
| Adjusted Gross profit | 854M | FY2025-Q4 |
| R&D | 84M | FY2025-Q4 |
| Non-GAAP Adjusted Gross Profit | 854M | FY2025-Q4 |
Back to OGN overview · OGN earnings · OGN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.